The role of circulating tumor DNA in melanomas of the uveal tract
2024

The Role of Circulating Tumor DNA in Uveal Melanoma

Sample size: 8033 publication 10 minutes Evidence: moderate

Author Information

Author(s): Zameer Mohammed Zeeshan, Jou Eric, Middleton Mark

Primary Institution: University of Oxford

Hypothesis

Can circulating tumor DNA (ctDNA) improve early detection and monitoring of uveal melanoma?

Conclusion

Circulating tumor DNA has the potential to enhance early detection and monitoring of uveal melanoma, which could lead to better patient outcomes.

Supporting Evidence

  • ctDNA levels correlated with disease burden in metastatic uveal melanoma patients.
  • Early detection of ctDNA may precede clinical diagnosis of metastasis by 2-10 months.
  • ctDNA can help predict treatment response and monitor disease progression.

Takeaway

This study looks at how a special type of DNA found in the blood can help doctors find and treat a serious eye cancer called uveal melanoma earlier.

Methodology

The review discusses existing evidence and potential clinical applications of ctDNA in uveal melanoma, including its use in diagnosis, monitoring, and treatment response.

Potential Biases

Potential biases may arise from the reliance on existing studies and the variability in ctDNA detection methods.

Limitations

Current use of ctDNA in uveal melanoma is largely limited to research settings, and further validation is needed for clinical application.

Participant Demographics

The study references a retrospective analysis of 8033 eyes with uveal melanoma.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI 53-70

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1509968

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication